Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iBio, Inc.IBIO · Entity 6906 | Chief Legal Officer | March 26, 2026 | March 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iBio, Inc.
Report date March 26, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Ending reported balance
After 2026-03-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-26 · Purchase · Acquired 12,500 · Balance 23,566 Row 2 · 2026-03-26 · Purchase · Acquired 1,434 · Balance 25,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2026 Filed Mar 27, 2026 16:05 UTC | iBio, Inc. IBIO · Entity 6906 | PurchaseCommon Stock | 1,434 | $1.76 | $2,523.84 |
DisclosureSEC source: 0001104659-26-036093 · tm269997-1_4seq1.xml · nonDerivative · entry 2 Banjak Marc · CIK 0002033869 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 16:05 UTC | iBio, Inc. IBIO · Entity 6906 | PurchaseCommon Stock | 12,500 | $1.64 | $20,531.25 |
DisclosureSEC source: 0001104659-26-036093 · tm269997-1_4seq1.xml · nonDerivative · entry 1 Banjak Marc · CIK 0002033869 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,566 Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 06:16 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 146,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001104659-26-008266 · tm264470-3_4seq1.xml · derivative · entry 1 Banjak Marc · CIK 0002033869 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Stock · 146,000 shares Expires 2036-01-27 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 18:28 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-25-101608 · tm2529309-2_4seq1.xml · derivative · entry 1 Banjak Marc · CIK 0002033869 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-10-19 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 06:01 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 71,000 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001104659-25-016311 · tm257339-3_4seq1.xml · derivative · entry 1 Banjak Marc · CIK 0002033869 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2035-02-20 F1 · security: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. F1 · derivative.exercise_date: These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 16:33 UTC | iBio, Inc. IBIO · Entity 6906 | PurchaseCommon Stock | 9,191 | $2.72 | $24,999.52 |
DisclosureSEC source: 0001104659-25-003062 · tm253156-5_4seq1.xml · nonDerivative · entry 1 Banjak Marc · CIK 0002033869 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,066 F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.